Actinogen Medical Ltd
ACW
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,889.80 | 16.00 | -0.18% |
| CAC 40 | 8,025.80 | 66.13 | 0.83% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 664.18 | 1.43% |
| FTSE 100 | 9,609.53 | 74.62 | 0.78% |
| HKSE | 26,051.75 | 157.20 | 0.61% |
| NASDAQ | 23,025.59 | 153.59 | 0.67% |
| Nikkei 225 | 49,503.74 | 844.22 | 1.73% |
| NZX 50 Index | 13,578.02 | 97.59 | 0.72% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,599.10 | 16.90 | -0.20% |
| SSE Composite Index | 3,867.80 | 2.22 | -0.06% |